

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-67022
Application Number	
Filing Date	
First Named Inventor	Ribaudo
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
MB		5,434,131	7/18/1995	Linsley et al.
		5,521,288	5/28/1996	Linsley et al.
		5,529,921	6/25/1996	Peterson et al.
		5,574,205	11/12/1996	Kucherlapati et al.
		5,580,756	12/3/1996	Linsley et al.
		5,582,831	12/10/1996	Shinitzky
		5,698,679	12/16/1997	Nemazee
		5,712,149	1/27/1998	Roberts
		5,733,550	3/31/1998	Rock
		6,183,734	2/6/2001	Chen et al.
		6,451,305	9/17/2002	Boussiotis et al.
		US 2002/0123108 A1	9/5/2002	Edwards et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
MB		0 733 373 A2	25.09.96	Europe
		WO 91/16924	14.11.91	WIPO
		WO 94/24290	27.10.94	WIPO

EXAMINER
SIGNATURE:




DATE
CONSIDERED:

4/26/07

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67022	
		Application Number		
		Filing Date		
		First Named Inventor	Ribaudo	
		Art Unit	Not yet assigned	
		Examiner Name	Not yet assigned	
FOREIGN PATENT DOCUMENTS				
Examiner's Initials*	Cite No. (optional)	Number	Date	Country
MB)		WO 97/24446	10.07.97	WIPO
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS		
MB 1		Bjorkman et al., "Structure of the Human Class I Histocompatibility Antigen, HLA-A2," <i>Nature</i> 329:506-512 (1987).		
		Freeman et al., "Murine B7-2, an Alternative CTLA4 Counter-Receptor that Costimulates T Cell Proliferation and Interleukin 2 Production," <i>J. Exp. Med.</i> 178:2185-2192 (1993).		
		Freeman et al., "Cloning of B7-2: A CTLA-4 Counter-Receptor that Costimulates Human T Cell Proliferation," <i>Science</i> 262:909-911 (1993).		
		Fukazawa et al., "The Effect of Mutant β_2 -Microglobulins on the Conformation of HLA-B27 Detected by Antibody and by CTL," <i>J. Immunol.</i> 153:3543-3550 (1994).		
		Gerstmayer et al., "Costimulation of T Cell Proliferation by a Chimeric B7-2 Antibody Fusion Protein Specifically Targeted to Cells Expressing the <i>erbB2</i> Proto-Oncogene," <i>J. Immunol.</i> 158:4584-4590 (1997).		
		Liu, "The Immunologist's Grail: Vaccines that Generate Cellular Immunity," <i>Proc. Natl. Acad. Sci. USA</i> 94:10496-10498 (1997).		
		Mottez et al., "Cells Expressing a Major Histocompatibility Complex Class I Molecule with a Single Covalently Bound Peptide Are Highly Immunogenic," <i>J. Exp. Med.</i> 181:493-502 (1995).		
		Rock et al., "Peptide-Priming of Cytolytic T Cell Immunity in Vivo Using β_2 -Microglobulin as an Adjuvant," <i>J. Immunol.</i> 150:1244-1252 (1993).		
		Shields et al., "The Effect of Human β_2 -Microglobulin on Major Histocompatibility Complex I Peptide Loading and the Engineering of a High Affinity Variant," <i>J. Biol. Chem.</i> 273:28010-28018 (1998).		
		Shields et al., "Characterization of the Interactions between MHC Class I Subunits: A Systematic Approach for the Engineering of Higher Affinity Variants of β_2 -Microglobulin," <i>J. Immunol.</i> 160:2297-2307 (1998).		
		Uger et al., "Creating CTL Targets with Epitope-Linked β -Microglobulin Constructs," <i>J. Immunol.</i> 160:1599-1605 (1998).		

EXAMINER SIGNATURE: 	DATE CONSIDERED: 4/26/07
--	-------------------------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.